CS MEDICA is a Danish medico cannabis company that envisions playing a central role in ensuring the best treatments within healthcare and wellness for patients, healthcare professionals, and consumers around the world. The Company fulfills this purpose by introducing and providing the most effective and innovative OTC cannabinoid products.

Following the Company's strategy of expanding its market shares, the Company aims to finalize distributor agreements outside of Denmark. Currently, the Company is in the process of entering markets across various nations in Europe. One of the ongoing order discussions regards the purchase and resale agreement with Kronans Apotek in Sweden. As of March 17, 2021, the Company has a purchase agreement with Kronans Apotek covering Cannasen® CBD Arthritis gel & Cannasen® CBD Psoriasis Gel.

Kronans Apotek is currently selling the products in their webshop. In accordance with the purchase agreement, the products are entering the shelf of the 326 local pharmacies of Kronans Apotek as of today, October 4.  The completion of this purchase agreement and fast track sales in Sweden will increase sales and distribution to meet financial targets. The Forecasted market value of treatment products containing CBD in Sweden is estimated to reach 0.5 billion euros in 2028. This purchase agreement not only increases sales and distribution but also helps CS MEDICA expand its market shares and brand visibility in Sweden.

This press release contains inside information that CS MEDICA A/S is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on October 4, 2021 at 13:19 CEST.